Efficacy and Tolerability of Besifloxacin Ophthalmic Suspension 0.6% Administered Twice Daily for 3 Days in the Treatment of Bacterial Conjunctivitis: A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study in Adults and Children

Clinical Therapeutics

Volumn 33, Issue 1, 2011, Pages 13-26

  Silverstein, Bruce E ^a   Allaire, Catherine ^b   Bateman, Kirk M ^b   Gearinger, Lynne S ^b   Morris, Timothy W ^b   Comstock, Timothy L ^b  

^a Shasta Eye Medical Group Inc   (United States)

^b BAUSCH AND LOMB   (United States)

Author keywords

Bacterial conjunctivitis; Bacterial eradication; Besifloxacin; BID; Clinical resolution; Fluoroquinolone

Indexed keywords

BESIFLOXACIN; DRUG VEHICLE;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; BACTERIAL INFECTION; BIOMICROSCOPY; CHILD; CLINICAL EVALUATION; CONJUNCTIVITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INSTILLATION; DRUG TOLERABILITY; EYE DISCHARGE; FEMALE; FOLLOW UP; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HORDEOLUM; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPHTHALMOSCOPY; OUTCOME ASSESSMENT; PATIENT; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZEPINES; CHILD; CHILD, PRESCHOOL; CONJUNCTIVITIS, BACTERIAL; DOUBLE-BLIND METHOD; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFANT; MALE; MICROSCOPY; MIDDLE AGED; OPHTHALMOSCOPY; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 79952531868     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.12.004     Document Type: Article

References (50)

1. Høvding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008, 86:5-17.
2. Rietveld R.P., ter Riet G., Bindels P.J., et al. Do general practitioners adhere to the guideline on infectious conjunctivitis?. Results of the Second Dutch National Survey of General Practice. BMC Fam Pract 2007, 8:54.
3. Sheikh A., Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2006, (2). CD001211.
4. Buznach N., Dagan R., Greenberg D. Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era. Pediatr Infect Dis J 2005, 24:823-828.
5. Rose P.W., Harnden A., Brueggemann A.B., et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: A randomised double-blind placebo-controlled trial. Lancet 2005, 366:37-43.
6. Tarabishy A.B., Jeng B.H. Bacterial conjunctivitis: A review for internists. Cleve Clin J Med 2008, 75:507-512.
7. Diamant J.I., Hwang D.G. Therapy for bacterial conjunctivitis. Ophthalmol Clin North Am 1999, 12:15-20.
8. Morrow G.L., Abbot R.L. Conjunctivitis. Am Fam Physician 1998, 57:735-746.
9. Besivance ophthalmic suspension 0.6% [US package insert] 2009, Bausch & Lomb, Inc, Tampa, Fla.
10. Besivance ophthalmic suspension 0.6% [Canadian product monograph] 2009, Bausch & Lomb, Inc, Vaughan, Canada.
11. Friedlaender M.H., Protzko E. Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy. Clin Ophthalmol 2007, 1:3-10.
12. Haas W., Pillar C.M., Zurenko G.E., et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 2009, 53:3552-3560.
13. Ward K.W., Lepage J.F., Driot J.Y. Non-clinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther 2007, 23:243-256.
14. Haas W., Pillar C.M., Hesje C.K., et al. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother 2010, 65:1441-1447.
15. Karpecki P., Depaolis M., Hunter J.A., et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther 2009, 31:514-526.
16. Tepedino M.E., Heller W.H., Usner D.W., et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin 2009, 25:1159-1169.
17. McDonald M.B., Protzko E.E., Brunner L.S., et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology 2009, 116:1615-1623.
18. Comstock T.L., Paterno M.R., Usner D.W., Pichichero M.E. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: A post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Paediatr Drugs 2010, 12:105-112.
19. Proksch J.W., Granvil C.P., Siou-Mermet R., et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther 2009, 25:335-344.
20. Leibowitz H.M. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol 1991, 112(Suppl):29S-33S.
21. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eighth edition. M07-A8 2009, Clinical and Laboratory Standards Institute, CLSI, Wayne, Pa.
22. Agresti A. Categorical Data Analysis 1990, John Wiley & Sons, New York, NY.
23. Schlech B.A., Stroman D.W., Gower L., Cupp G. Eradication of bacteria from infected eyes by a three day BID treatment with moxifloxacin ophthalmic solution, 0.5%. Invest Ophthal Vis Sci 2003, 44. E-abstract 2116.
24. Gross R.D., Lichtenstein S.J., Schlech B.A. Early clinical and microbiological responses in the treatment of bacterial conjunctivitis with moxifloxacin ophthalmic solution 0.5% (vigamox) using BID dosing. Todays Ther Trends 2003, 21:227-237.
25. Zymaxid (gatifloxacin ophthalmic solution) 0.5% [package insert] 2010, Allergan, Inc, Irvine, Calif.
26. Hwang D.G., Schanzlin D.J., Rotberg M.H., et al. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol 2003, 87:1004-1009. Levofloxacin Bacterial Conjunctivitis Placebo-Controlled Study Group.
27. Katz H.R., Andrews W., Creager D., et al. Moxifloxacin ophthalmic solution 0.5% hastens cure and eradicates the causative pathogens of bacterial conjunctivitis in pediatric and adult patients. Invest Ophthal Vis Sci 2003, 44. E-abstract 2114.
28. Yee R.W., Tepedino M., Bernstein P., et al. A randomized, investigator-masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment of acute bacterial conjunctivitis. Curr Med Res Opin 2005, 21:425-431. Gatifloxacin BID/QID Study Group.
29. Szaflik J., Szaflik J.P., Kaminska A. Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis. Eur J Ophthalmol 2009, 19:1-9. Levofloxacin Bacterial Conjunctivitis Dosage Study Group.
30. Haas W, Pillar C, Torres M, et al. ARMOR, a new prospective, multicenter surveillance study to determine the in vitro activity profile of besifloxacin and comparators against ocular pathogens from the US. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology; May 2-6, 2010; Fort Lauderdale, Fla.
31. Chang JS, Flynn HW Jr, Miller D, Alfonso EC. Evaluation of in vitro effectiveness of besifloxacin against Staphylococcus epidermidis. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology; May 2-6, 2010; Fort Lauderdale, Fla.
32. Miller D. In vitro evaluation of besifloxacin against ciprofloxacin and moxifloxacin resistant/susceptible staphylococcal isolates from South Florida. Presented at: 5th International Conference on Ocular Infections; February 18-21, 2010; Palm Beach, Fla.
33. Gearinger LS, Haas W, Morris TW. In vitro activity of besifloxacin, ciprofloxacin, gatifloxacin, levofloxacin, and moxifloxacin against ciprofloxacin-resistant ocular Staphylococcus aureus and Staphylococcus epidermidis. Presented at: 5th International Conference on Ocular Infections; February 18-21, 2010; Palm Beach, Fla.
34. Haas W, Zurenko GE, Lee J, et al. Activity of besifloxacin and competitors against ciprofloxacin resistant Staphylococcus aureus and Staphylococcus epidermidis ocular isolates from 2005-2008. Presented at: 3rd Congress of the Federation of European Microbiologists; June 28-July 2, 2009; Göteborg, Sweden.
35. McDonald M., Blondeau J. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones. J Cataract Refract Surg 2010, 36:1588-1598.
36. Asbell P.A., Colby K.A., Deng S., et al. Ocular TRUST: Nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008, 145:951-958.
37. Asbell P.A., Sahm D.F., Shaw M., et al. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005. J Cataract Refract Surg 2008, 34:814-818.
38. Adebayo A, Parikh JG, McCormick SA, et al. Shifting trends in in vitro antibiotic susceptibilities for common bacterial isolates in the last decade at the New York Eye and Ear Infirmary [E-pub ahead of print: June 8, 2010]. Graefes Arch Clin Exp Ophthalmol.
39. Freidlin J., Acharya N., Lietman T.M., et al. Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus. Am J Ophthalmol 2007, 144:313-315.
40. Blomquist H.P. Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2008, 104:322-345.
41. Comstock T.L., Paterno M.R., Decory H.H., Usner D.W. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: Data from six clinical and phase I safety studies. Clin Drug Investig 2010, 30:675-685.
42. Drug Facts and Comparisons 2008 2007, Lippincott Williams & Wilkins, Philadelphia, Pa.
43. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
44. Ingersoll K.S., Cohen J. The impact of medication regimen factors on adherence to chronic treatment: A review of literature. J Behav Med 2008, 31:213-224.
45. Richter A., Anton S.E., Koch P., Dennett S.L. The impact of reducing dose frequency on health outcomes. Clin Ther 2003, 25:2307-2335.
46. Cavuoto K., Zutshi D., Karp C.L., et al. Update on bacterial conjunctivitis in South Florida. Ophthalmology 2008, 115:51-56.
47. Harbarth S., Samore M.H. Antimicrobial resistance determinants and future control. Emerg Infect Dis 2005, 11:794-801.
48. Blondeau J.M., Hansen G., Metzler K., Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: Mutant prevention concentration. J Chemother 2004, 16(Suppl 3):1-19.
49. McDonnell G., Russell A.D. Antiseptics and disinfectants: Activity, action, and resistance [published correction appears in Clin Microbiol Rev. 2001;14:227]. Clin Microbiol Rev 1999, 12:147-179.
50. Blondeau J.M., Boros S., Hesje C.K. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus. J Chemother 2007, 19:146-151.